Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising results in initial clinical assessments . Ongoing https://rotatesites.com/story22893063/retatrutide-emerging-studies-and-projected-therapeutic-roles